At a glance
- Originator ProlX Pharmaceuticals
- Developer Oncothyreon
- Class Amines; Antineoplastics; Chlorinated hydrocarbons; Mustard compounds; Phenylpropionates; Small molecules
- Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Solid tumours
Most Recent Events
- 08 Jun 2010 Efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a Phase-I trial in Cancer presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010) ,
- 14 May 2010 Oncothyreon completes a phase I trial in Solid tumours and lymphoma in USA
- 16 Apr 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,,